Articles dans des revues avec comité de lecture (396)
  1. 85. Gombos, A., & Awada, A. (2017). Advances in chemical pharmacotherapy to manage advanced breast cancer. Expert opinion on pharmacotherapy, 18(1), 95-103. doi:10.1080/14656566.2016.1269748
  2. 86. Locatelli, M. A., Shaik, M. N., Kern, K. K., Curigliano, G., Aftimos, P., Claire Dees, E., LoRusso, P. M., Pegram, M., Awada, A., Huang, B., Cesari, R., & Jiang, Y. (2017). Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triplenegative breast cancer. Oncotarget, 8(2), 2320-2328. doi:10.18632/oncotarget.13727
  3. 87. Fakhruddin, N., Bahmad, H. H., Aridi, T., Yammine, Y., Mahfouz, R., Boulos, F., Awada, A., & Farhat, F. S. (2017). Hepatoid Adenocarcinoma of the Stomach: A Challenging Diagnostic and Therapeutic Disease through a Case Report and Review of the Literature. Frontiers in Medicine, 4, 164. doi:10.3389/fmed.2017.00164
  4. 88. Wildiers, H., Duhoux, F. F., Awada, A., & de Azambuja, E. (2017). Systemic chemotherapy regimens in early breast cancer patients: updated recommendations from the BSMO breast cancer task force. Belgian journal of medical oncology, 11(8), 375-379.
  5. 89. Solinas, C., Garaud, S., De Silva, P., Boisson, A., Van den Eynden, G., de Wind, A., Risso, P., Rodrigues Vitória, J., Richard, F., Migliori, E., Noel, G., Duvillier, H., Ruscas-Craciun, L. I., Veys, I., Awada, A., Detours, V., Larsimont, D., Piccart-Gebhart, M., & Willard-Gallo, K. (2017). Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. Frontiers in immunology, 8, 1412. doi:10.3389/fimmu.2017.01412
  6. 90. Cortes, J., Buchanan, J., Tagliaferri, M., Hannah, A. L., O'Shaughnessy, J., Rugo, H., Twelves, C., Awada, A., Perez, E. A., Im, S. A., Zhao, C., Hoch, U., & Tomkinson, D. (2016). Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. SpringerPlus, 5(1), 1033. doi:10.1186/s40064-016-2446-4
  7. 91. Kanaan, H., Kourie Hampig, R., & Awada, A. (2016). Are virus-induced cancers more sensitive to checkpoint inhibitors? Future oncology, 12(23), 2665-2668. doi:10.2217/fon-2016-0283
  8. 92. Awada, A., Bachelot, T., Goswami, C., Deo, S., Bose, R., Wong, A., Xu, F., Yao, B., Bryce, R., Carey, L. L., Colomer, R., Inoue, K., Bondarenko, I. I., Badwe, R., Demetriou, G., Lee, S. C., Mehta, A. A., & Kim, S.-B. (2016). Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. JAMA oncology, 2(12), 1557-1564. doi:10.1001/jamaoncol.2016.0237
  9. 93. Cairns, L., Aspeslagh, S., Anichini, A., Kyte, J. A., Blank, C., Ascierto, P., Rekers, N., Straten, P. T., & Awada, A. (2016). Cancer immunotherapy: From the lab to clinical applications - Potential impact on cancer centres' organisation. ecancermedicalscience, 10, 691. doi:10.3332/ecancer.2016.691
  10. 94. Tolaney, S. S., Winer, E. E., Nechushtan, H., Ron, I. G., Schöffski, P., Awada, A., Yasenchak, C. C., Laird, A. D., O’Keeffe, B., & Shapiro, G. G. (2016). Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. Breast cancer research and treatment, 160(2), 305-312. doi:10.1007/s10549-016-4001-y
  11. 95. Aspeslagh, S., Awada, A., Matos-Pita, A. A., Aftimos, P., Bahleda, R., Varga, A., & Soria, J.-C. (2016). Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors. Anti-cancer drugs, 27(10), 1021-1027. doi:10.1097/CAD.0000000000000409
  12. 96. Deliens, C., Deliens, G., Filleul, O., Pepersack, T., Awada, A., Piccart-Gebhart, M., Praet, J. P., & Dal Lago, L. (2016). Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist. Journal of geriatric oncology, 7(6), 463-470. doi:10.1016/j.jgo.2016.05.001
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>